Biologically Active Substance

Eli Lilly Blows Past Revenue Benchmarks, Again Raises Full-Year Outlook

4 days ago talkbio0Tagged earnings, eli lilly, exophthalmos producing substance, full-year guidance, Mounjaro, pharmaceutical innovation, Q3, revenue growth, Weight-Loss Agents, Zepbound

Eli Lilly; Q2 2025 earnings; Q3 2025 earnings; Mounjaro; Zepbound; weight-loss drugs; revenue growth; EPS; full-year guidance; pharmaceutical innovation

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

4 days ago talkbio0Tagged Antibodies, Bispecific, biobucks, China, COPD, IL33 protein, human, Preclinical, Qyuns Therapeutics, Respiration Disorders, Roche (company), TSLP gene

Roche; Qyuns Therapeutics; bispecific antibody; COPD; preclinical; TSLP; IL-33; China biotech; biobucks; respiratory disease

Vistagen Appoints Paul Edick to its Board of Directors

4 days ago talkbio0Tagged Audit Committee, Biological Factors, board of directors, Compensation Committee, Corporate governance, Drug Industry, Paul Edick, Vistagen

Vistagen; Paul Edick; Board of Directors; Audit Committee; Compensation Committee; Biopharmaceutical; Pharmaceutical industry; Corporate governance

Step Pharma Appoints Dr. Karen L. Smith as Chief Medical Officer

5 days ago talkbio0Tagged Biological Factors, Chief Medical Officer, Clinical Development, CTPS1 inhibitor, dencatistat, Karen Smith, Neoplasms, Regulatory Affairs, Step Pharma

Step Pharma; Karen Smith; Chief Medical Officer; CTPS1 inhibitor; dencatistat; oncology; clinical development; biopharmaceutical; regulatory affairs

BridgeBio Shifts Filing Plans After Phase 3 Success in Rare Disease Drug BBP-418

6 days ago talkbio0Tagged Acoramidis, Approved, BBP-418, Biological Markers, BridgeBio, commercial, disease drug, File (record), Infrequent, Limb-girdle muscular dystrophy type 2A, NDA, New Drug Application, Phase 3 success, Ribitol, United States Food and Drug Administration

BridgeBio; BBP-418; Phase 3 success; limb-girdle muscular dystrophy type 2I/R9; FDA filing; rare disease drug; NDA (New Drug Application); ribitol; full approval; biomarker; acoramidis; commercial strategy

FDA Rejects Sydnexis Myopia Drug for Kids; Chugai to Buy Renalys for $98M Upfront

1 week ago talkbio0Tagged Chugai, Complete Response Letter, methionine, Myopia, Ophthalmology specialty, Pediatric brand name, Renalys, SYD-101, Sydnexis, United States Food and Drug Administration

FDA; SYD-101; Sydnexis; myopia; pediatric; complete response letter; Chugai; Renalys; acquisition; $98M; ophthalmology

Inhibrx to Seek FDA Approval in 2026 After Strong Phase 2 Data for Bone Cancer Drug Ozekibart

1 week ago talkbio0Tagged Anti-DR5 Agonistic Monoclonal Antibody INBRX-109, Biological Factors, Chondrosarcoma, Infrequent, Inhibrx, Liver, Malignant Bone Neoplasm, Malignant Neoplasms, ozekibart, Progression-Free Survival, Receptors, Tumor Necrosis Factor, Member 10b, Submission, Toxicity aspects, United States Food and Drug Administration

Inhibrx; FDA submission; ozekibart; INBRX-109; chondrosarcoma; bone cancer; phase 2 clinical trial; progression-free survival; death receptor 5; biologics license application; rare cancer; liver toxicity

Rani Therapeutics Appoints Abe Bassan and Vasudev Bailey to Board of Directors

1 week ago talkbio0Tagged Abe Bassan, Anomaly Ventures, BioCapital, Biological Factors, biotherapeutics, Board change, board of directors, Chugai, Collaboration, Obstetric Delivery, Oral cavity, Rani Therapeutics, Samsara, Vasudev Bailey

Rani Therapeutics; Board of Directors; Abe Bassan; Vasudev Bailey; biotherapeutics; oral biologics delivery; Samsara BioCapital; Anomaly Ventures; Chugai collaboration; Board change

Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025

2 weeks ago talkbio0Tagged ACR-2316, Acrivon, AP3, Conferences, Generative Phosphoproteomics, Inhibitor, KaiSR, partial response, PKMYT1 protein, human, Platform, PLK1 gene, precision oncology, preclinical data, Study models, WEE1 inhibitor

Acrivon Therapeutics; AP3 platform; Generative Phosphoproteomics; KaiSR model; ACR-2316; AACR-NCI-EORTC conference; preclinical data; partial response; WEE1 inhibitor; PKMYT1 inhibitor; PLK1; precision oncology

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

2 weeks ago talkbio0Tagged Biological Factors, conditions, Dilution technique, Gross (qualifier value), Immunology, Market, Pricing, public entity, RAPT

RAPT Therapeutics; public offering; common stock; underwritten offering; biopharmaceutical; immunology; market conditions; share dilution; offering pricing; gross proceeds